| 08:15 |  | 0770. Pulmonary MR angiography with gadopiclenol can reduce gadolinium exposure while maintaining signal enhancement. J. Heidenreich, S. Chu, J-P Grunz, J. Starekova, P. Nagpal, S. Reeder, T. Grist
University Madison Wisconsin, Madison, United States Impact: The use of high relaxivity gadopiclenol can reduce gadolinium exposure by 50% while maintaining adequate contrast enhancement. This may improve the safety and sustainability of gadolinium-enhanced MRA. |
| 08:27 |  | 0771. Gadolinium Nanoparticle with Blood Pool Properties for Whole Body MRA to Support 60-Minute Image Acquisition Time J. Reddington, A. Lang, J. Thorball, R. Ho, U. Schmiedl
Hawkeye MRI AG, Pfäffikon SZ, Switzerland Impact: A blood pool lipid-based GBCA allows superior vascular
images at 1.5 or 3T. Lower doses of gadolinium and
route of excretion are of potential safety benefit, and longer imaging times
provide greater flexibility and expanded radiological applications. |
| 08:39 |  | 0772. Novel biological Gadolinium contrast agents for MRI developed using artificial intelligence N. Dayan, N. Scalzitti, I. Miralavy, W. Banzhaf, A. Gilad
Michigan State University, East Lansing, United States Impact: The Gadolinium binding motifs found in this research will be used to develop biological MRI contrast agents that will allow safer and more effective imaging procedures. |
| 08:51 |  | 0773. Long-Term Effects of Linear versus Macrocyclic Gadolinium-Based Contrast Agents on Gene Expression in the Central Nervous System of Mice c. wang, s. wang
The First Affiliated Hospital of Nanjing Medical University, nanjing, China Impact: Our study pioneers in detecting genetic and protein-level changes in the central nervous system from prolonged gadolinium accumulation, highlighting the need for further research to understand mechanisms and assess the long-term safety of linear GBCAs. |
| 09:03 |  | 0774. Metal-Organic Supramolecular Cage based Microenvironment Responsive Nanomedicine for Photodynamic Therapy of Triple-Negative Breast Cancer D. Li, X. Yan, Y. Su, X. Chen, J. Peng, F. Zeng, J. Shen
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, guangzhou, China Impact: Nano
carriers (MM) exhibit significant MRI - monitoring ability in vivo during the
treatment process, with a longer imaging window and good PDT effects. These MRI
- related features show great potential as a therapeutic - diagnostic platform
for TNBC treatment using nanomedicine. |
| 09:15 |  | 0775. Liver Tumor Differentiation Enhanced by Adding Hepatobiliary Phase MR Fingerprinting: A Multi-parametric Diagnostic Approach K. Sano, S. Fujita, G. Cruz, C. Velasco, D. Pedraza, H. Kawasaki, Y. Fukumura, A. Suzuki, Y. Ikenouchi, T. Arai, Y. Morita, W. Uchida, A. Saiura, K. Ikejima, K. Kamagata, R. Kuwatsuru, R. Botnar, C. Prieto, S. Aoki
Juntendo University, Tokyo, Japan Impact: Incorporating a multi-parametric approach with MRF during the hepatobiliary phase of gadoxetic acid-enhanced MRI improves diagnostic accuracy in liver tumor differentiation, potentially reducing reliance on dynamic phases and enhancing non-invasive diagnostic capabilities in clinical liver assessments. |
| 09:27 |  | 0776. Free-breathing 3D High-resolution Simultaneous Grey-blood Late Gadolinium Enhancement and MR Angiography at 3T D. Si, S. Littlewood, M. Crabb, K. Kunze, C. Prieto, R. Botnar
School of Biomedical Engineering and Imaging Sciences, King's College London, London, United Kingdom Impact: The
proposed sequence can achieve co-registered 3D whole-heart grey-blood late
gadolinium enhancement and cardiac MR angiography at a resolution of 1.2mm3
in a single fast scan of approximately 10 mins with comparable image
quality as separately acquired images. |
| 09:39 |  | 0777. Quantitative characterization of background parenchymal enhancement in abbreviated breast MRI acquired with a high relaxivity contrast agent F. Pineda, Y. Cao, A. Lu, M. Zuley
University of Pittsburgh, Pittsburgh, United States Impact: Abbreviated breast MRIs acquired with 0.05mmol/kg gadopiclenol showed slightly higher levels of signal enhancement in background parenchyma than those acquired with 0.1mmol/kg gadoteridol. Further investigation is underway to determine whether these differences lead to a higher false positive rate. |
| 09:51 |  | 0778. R1, R2 and R2* Relaxivity Measurements of the Contrast Agent Gadopiclenol in Human Blood; Application to Administration Strategies J. Maki, T. Clark, A. Barker, G. Wilson
University of Colorado, Aurora, United States Impact: Different GBCAs have different relaxivity properties in blood. Knowledge of these properties allows for accurate modeling and optimization of exams such as CE-MRA, 1st pass arterial phase imaging and perfusion. |
| 10:03 |  | 0779. Implementation of gadolinium saving potential utilizing Gadopiclenol in vasculitis imaging T. Bley, R. Dazeh, M. Schmalzing, M. Gernert, K. Guggenberger, V. Hartung
University Medical Center Wuerzburg, Wuerzburg, Germany Impact: Gadolinium usage could now be reliably reduced by half utilizing half dose Gadopiclenol while maintaining clinically needed high contrast in vasculitis imaging and aortic imaging, a previously unmet need by other contrast agents. |